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For some time now, scientists have predicted the emergence of “Disease X”, a hypothetical unknown disease 
agent that would be capable of causing 
a future epidemic. In December 2019, 
the world woke up to the news of a new 
virus. Initially referred to as the 2019 
novel coronavirus, it was later renamed as 
SARS-CoV-2. 
A novel coronavirus
The ‘SARS’ in its name reflects the 
symptoms this virus produces in 
some infected people — Severe Acute 
Respiratory Syndrome, and ‘CoV-2’ 
refers to the fact that it is the second 
coronavirus found to produce these 
symptoms (the first one emerged in 
2002-03 and was called SARS-CoV). 
Coronaviruses are a group of viruses  
with surface spikes, visible under a very 
high-powered electron microscope, that 
give them a solar corona or crown-like 
(hence the name) appearance (see Fig. 1). 
The disease this virus causes is called 
Coronavirus Infectious Disease 2019, 
abbreviated as COVID-19.
Coronaviruses cause acute and persistent 
infections in humans, other mammals, 
and birds. Members of this family were 
isolated from animals as early as in the 
1930s. But it was only in the 1960s that 
some viruses causing respiratory disease 
in humans were discovered to be part of 
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How do we know that 
SARS-CoV-2 is a 'novel' 
coronavirus? How was 
this virus discovered? 
What do we know 
about its structure? 
How long can it remain 
infectious outside a 
host cell? Is there any 
evidence to suggest that 
SARS-CoV-2 may have 
originated in a lab? 
Fig. 1. Electron micrograph of SARS-CoV-2 
particles with visible coronae. Virus particles 
are shown emerging from the surface of cells 
cultured in the lab. 
Credits: NIAID Rocky Mountain Laboratories (RML), 
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this family. Four human coronaviruses 
were identified as being endemic in the 
human population. These cause about 
20% of common colds annually. 
Novel viruses are emerging all the 
time, but come into prominence only 
when they cause disease in humans or 
other animal species. In the past two 
decades, three new human coronaviruses 
have emerged, all from bats, to cause 
outbreaks in different parts of the world. 
These include the SARS-CoV in 2002-03 
in China, the Middle East Respiratory 
Syndrome Coronavirus (MERS-CoV) 
in Saudi Arabia in 2012, and the most 
recent SARS-CoV-2 in China in 2019. 
All these viruses have similar physical 
attributes and genome organization, 
but differ in their genetic sequences. 
For example, SARS-CoV-2 has ~80% 
sequence identity with SARS-CoV, but 
only ~55% to MERS-CoV, and ~50% to 
the common cold coronaviruses.
What do we know  
about SARS-CoV-2?
In late 2019, doctors in China’s Hubei 
Province, and its main city Wuhan, 
started seeing a cluster of patients 
with pneumonia. This is an infection 
of the lung in which the air sacs are 
inflamed and may fill with fluid or 
pus, causing cough, fever, chills, and 
breathing difficulties (see Fig. 2). While 
pneumonia is seen in infections by 
many microorganisms (bacteria, viruses, 
and fungi), genetic sequencing of fluid 
from the lungs of patients from Wuhan 
always showed the presence of virus 
sequences similar, but not identical, to 
SARS-CoV. The virus was isolated from 
cell cultures infected with fluids from 
the lungs, throat, and nasal cavity of 
patients. Thus, powerful detection tools, 
cell culture, and genetic sequencing 
technologies ensured that the virus was 
identified within just a few weeks. 
Like other coronaviruses, SARS-CoV-2 
is a particle of about 100 nanometers 
(1 nanometer = 10–9 meter) in size. This 
enveloped virus has three different 
proteins — the Spike (S), Envelope 
(E), and Membrane (M) proteins — 
embedded in its lipid (fat) envelope. 
It is the S proteins that give the virus 
its corona-like appearance. Within 
the envelope, a single strand of RNA 
of about 30,000 bases or nucleotides 
is tightly wrapped around multiple 
copies of the Nucleocapsid (N) protein 
(see Fig. 3). During infection, the virus 
RNA enters a host cell, replicates, and 
directs the synthesis of about 24-
27 proteins that allow the virus to 
multiply. Some of these proteins, like 
the viral replicase enzyme and the S, E, 
M and N proteins, help in direct ways. 
Several nonstructural proteins, such as 
the Orf3a protein, help indirectly by 
modifying cellular processes in the host 
to better replicate the virus. 
While a genome of 30,000 bases in 
coronaviruses is unusually large for 
an RNA virus (most are about a third 
of this), its size is not important for 
transmission or severity of disease. Large 
population sizes and a high frequency 
of errors introduced during genome 
replication mean that viruses tend to 
show high mutation rates. In general, 
RNA viruses mutate even faster than 
DNA viruses because their replicases 
(enzymes which catalyze the synthesis 
of a complementary RNA molecule 
Fig. 2. The discovery of COVID-19 was sparked by a cluster of patients with pneumonia in 
Wuhan, China. Lung infection can lead to fluid accumulation in air sacs that results in 
breathing difficulties. 
Credits: National Institutes of Health, United States Department of Health and Human Services, Wikimedia 
Commons. URL: https://commons.wikimedia.org/wiki/File:New_Pneumonia_cartoon.jpg. License: CC-BY. 
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using an RNA template) lack an error-
correction function. Higher mutation 
rates lead to more diverse virus 
populations, some of which randomly 
acquire the ability to survive or transmit 
better. However, due to an enzyme that 
repairs replication errors, coronaviruses 
tend to have lower mutation rates that 
are, for example, about 1000 times 
lower than that for influenza viruses 
(also RNA viruses). 
As of now, only one strain of SARS-
CoV-2 is circulating globally. But this 
strain has multiple groups (or clades) of 
isolates, which often show variations 
in geographic distribution. Since its 
emergence, one mutant of the virus, 
with an aspartic acid to glycine change 
at amino acid 614 in a Spike protein, 
has spread faster than others. Scientists 
believe that this mutation (called 
D614G) has increased both the stability 
of the Spike protein trimers and their 
ability to bind cell surface receptors for 
productive infection. 
Since a virus is “living” only when inside 
a host cell, we call it either infectious 
or noninfectious when outside (see 
Box 1). SARS-CoV-2 can stay infectious 
on surfaces for variable times at room 
temperature — up to 4 hours on copper, 
24 hours on cardboard, and 72 hours on 
plastic and stainless steel. In laboratory 
tests, SARS-CoV-2 can be inactivated 
within seconds at temperatures of 90oC 
or above. It is highly stable at 4oC, and 
stays infectious at 22oC for 7 days, 37oC 
for 1 day, 56oC for 10 min, and 70oC for 
1 min. A 1:100 dilution of household 
bleach (4% sodium hypochlorite) is 
helpful in disinfecting surfaces, but 
should not be used on human skin as it 
can cause irritation, especially in the eyes.
Origin of SARS-CoV-2
Where did SARS-CoV-2 come from? 
Evidence indicates that it jumped into 
humans from bats, either directly or via 
another animal species (in this case, the 
pangolin — a scaly mammal whose flesh 
is eaten in China, and scales are used in 
Chinese traditional medicine).
What is the evidence? The SARS-CoV-2 
genome has 96% sequence identity 
to coronaviruses isolated from bats 
in eastern China in 2018, and 91% 
identity to coronaviruses isolated from 
pangolins. This is much higher than its 
genetic identity to SARS-CoV (~80%), 
MERS-CoV (~55%) and other human 
coronaviruses (~50%), suggesting that 
SARS-CoV-2 is not derived from the 
earlier human viruses. Two key features 
in the Spike proteins of SARS-CoV-2 
allow it to bind human cells and 
transmit efficiently. One of these is 
found in Pangolin-CoV, but both are 
missing from Bat-CoV. The most likely 
scenario is that a progenitor of SARS-
CoV-2 jumped to humans from bats, 
possibly through pangolins. The virus 
then mutated and evolved in humans, 
till such time that it became capable 
of efficient transmission, and started 
causing widespread respiratory disease. 
Was SARS-CoV-2 developed in a lab? If 
one tried to develop a highly pathogenic 
Box 1. Protection from SARS-CoV-2 infection:
There are three important guidelines to protect from infection.
1. Masks: Though viruses are extremely small (nanometers) and are able to pass 
through very fine filters, SARS-CoV-2 and other respiratory viruses are released 
in large and small droplets while coughing, sneezing, speaking, or even breathing. 
Inhaling these droplets can infect a susceptible person. Wearing a mask, even a 
home-made cloth one, allows an infected person to contain the release of these 
droplets, and a susceptible person to prevent exposure. If both wear masks, the 
chances of transmission are negligible.
2. Physical distancing: Maintaining a distance of at least 2 m (or 6 feet) limits 
exposure to large droplets, loaded with the virus, from an infected person.
3. Hand hygiene: Virus-carrying droplets can contaminate surfaces such as door 
knobs, tabletops, etc. When a susceptible person touches these surfaces, the virus 
is transferred to their hands and, eventually, finds its way to their mouth or nose. 
Since SARS-CoV-2 has a lipid (fat) membrane, washing hands with soap and water 
destroys it just like soap cuts through grease. Hand sanitizers with about 70% 
alcohol are also helpful.
Fig. 3. Artist’s model of a SARS-CoV-2 particle. An estimated 100 trimers (or 300 monomers) 
of S, about 2000 copies of M, and about 20 copies of E are deeply embedded in the lipid 
envelope of each virus particle. Within the envelope, an RNA strand of 30,000 bases is tightly 
wrapped around multiple copies of the Nucleocapsid (N) protein. 
Credits: Created by Maya Peters Kostman for the Innovative Genomics Institute. URL: https://
innovativegenomics.org/wp-content/uploads/2020/04/Single-virion-with-all-parts-labeled.png. License: 
CC-BY-NC-SA.
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coronavirus, the logical starting point 
would be another human coronavirus, 
not an obscure bat or pangolin virus 
that has never been found to cause 
disease in humans. The Nobel laureate 
Prof. Luc Montagnier has referred to the 
presence of elements of both the HIV-1 
retrovirus and the malarial parasite 
Plasmodium falciparum in the SARS-
CoV-2 genome. These short sequences, 
as discovered by scientists in 2005, 
are required for genome replication 
by many coronaviruses. Researchers in 
India also pointed this out erroneously 
and retracted their results. There is no 
credible evidence that SARS-CoV-2 was 
developed in a lab. All available evidence 
seems to point to this virus being a 
product of natural evolution.
Parting thoughts
Can a bat virus jump into humans 
again? Absolutely. So can viruses from 
rodents, monkeys, and other mammals. 
We must, therefore, carry out routine 
surveillance of our ecosystems to 
recognize potential jumps well in 
advance. For example, India has 117 
indigenous species of bats, but we 
know very little about the viruses they 
harbour. Killing bats or other animals 
is not the solution; they have valuable 
roles in our ecosystem. Surveillance and 
ensuring that their habitats (i.e., forests) 
are not destroyed will reduce animal-
human contact, and reduce the risk 
of animal viruses getting into human 
populations. This is the only way to 
avoid future disease outbreaks.
• SARS-CoV-2 gets its name from the fact that it is the second coronavirus known to cause Severe 
Acute Respiratory Syndrome in humans. Like other coronaviruses, SARS-CoV-2 is an RNA virus 
with a crown-like appearance when viewed under an electron microscope.
• While SARS-CoV-2 has an unusually large genome, its mutation rate is on average lower than 
other RNA viruses. As of now, only one strain of SARS-CoV-2 is circulating globally, and one 
mutation (called D614G) has spread faster than others. 
• SARS-CoV-2 can stay infectious on a variety of surfaces for variable durations, but can be easily 
killed with soaps or disinfectants.
• There is no credible evidence that SARS-CoV-2 was created in a lab. All available evidence points 
to it being a product of natural evolution that originated in bats, and jumped to humans directly, 
or via pangolins. 
• Future outbreaks of zoonoses from wild animals can be avoided by routine surveillance of 
ecosystems and ensuring that their (forest) habitats are not destroyed.
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